Clinical

Arash Mostaghimi highlighted the scientific journey that led to Janus kinase (JAK) inhibitors becoming a treatment avenue for alopecia areata, beginning with a case report by Brett King in which a patient with psoriatic arthritis receiving tofacitinib experienced complete scalp hair regrowth despite also having AA.

The expert clinician examined the multidisciplinary approach to alopecia areata care, with the board-certified dermatologist serving as the central coordinator, supported by pediatricians and family practice providers for early recognition and timely referral, dermatopathologists for cases requiring biopsy, and specialists in endocrinology, rheumatology, and psychiatry or psychology for management of associated comorbidities and psychosocial needs.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

The panelist discussed the SALT scoring system, which divides the scalp into four regions — the frontal parietal scalp, bilateral preauricular and postauricular scalp, and posterior scalp — and evaluates the percentage of hair loss in each area to produce a composite score ranging from 0 to 100, with a score below 20 serving as the primary efficacy benchmark in JAK inhibitor clinical trials.

The panelist examined the wide-ranging burden of alopecia areata on patients and their families, including the challenges of accessing specialist care, navigating prior authorization processes, and the financial strain faced by uninsured or underinsured patients who cannot access the three FDA-approved Janus kinase (JAK) inhibitors now available for this condition.

Dr. Amy McMichael highlighted the clinical presentation of alopecia areata, describing the characteristic patchy, round hair loss that can progress to more extensive forms including ophiasis, alopecia totalis, and alopecia universalis, with associated symptoms such as burning, stinging, conjunctivitis, and worsening allergic reactions from loss of eyelash and nasal hairs.

In patients with NSCLC, 3+1 lymph node sampling was not linked to higher postoperative complications, supporting guideline adherence.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages.

The panelists highlighted how stigma, misdiagnosis, and the concentration of mental health care in primary care settings collectively contribute to significant delays in patients receiving appropriate psychiatric treatment for MDD, bipolar depression, and schizophrenia.

Learn why CKD often goes undiagnosed in type 2 diabetes and how UACR screening plus obesity therapies can cut cardiovascular risk.

Uncover hidden CKD in type 2 diabetes: boost UACR screening, close diagnosis-to-treatment gaps, and navigate modern obesity therapies.

The dual glucagon/GLP-1 receptor agonist is also being studied in the SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE, and LIVERAGE-Cirrhosis trials.

Real-world diabetic macular edema care lags trials as fewer VEGF injections and step therapy limit outcomes.

Research from Samuel Shangwu Wu, PhD, presented as an ADA Presidents' Select Abstract, proposes a better way to measure beta-cell preservation.

Factor XIa inhibitors emerge as safer stroke prevention, cutting harmful clots without excess bleeding—see which oral and IV drugs reach phase 3.

Learn how anticoagulants, antiplatelets, and atrial appendage closure prevent repeat ischemic stroke—and why early follow-up boosts adherence.

Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.

ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.

Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors.

ADA 2026 data show survodutide cut visceral fat by 34% and liver fat by 63%, suggesting metabolic benefits beyond weight loss in phase 3 trials.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician awareness remains a key barrier.

Covering delgocitinib for chronic hand eczema could save a 1M-member plan $88M over 3 years, driven by lower drug costs than off-label therapies.

The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention landscape.